Literature DB >> 11248291

Analysis of the activated partial thromboplastin time test using mathematical modeling.

A E Kogan1, D V Kardakov, M A Khanin.   

Abstract

Activated partial thromboplastin time (APTT) is a laboratory test for the diagnosis of blood coagulation disorders. The test consists of two stages: The first one is the preincubation of a plasma sample with negatively charged materials (kaolin, ellagic acid etc.) to activate factors XII and XI; the second stage begins after the addition of calcium ions that triggers a chain of calcium-dependent enzymatic reactions resulting in fibrinogen clotting. Mathematical modeling was used for the analysis of the APTT test. The process of coagulation was described by a set of coupled differential equations that were solved by the numerical method. It was found that as little as 2.3 x 10(-9) microM of factor XIIa (1/10000 of its plasma concentration) is enough to cause the complete activation of factor XII and prekallikrein (PK) during the first 20 s of the preincubation phase. By the end of this phase, kallikrein (K) is completely inhibited, residual activity of factor XIIa is 54%, and factor XI is activated by 26%. Once a clot is formed, factor II is activated by 4%, factor X by 5%, factor IX by 90%, and factor XI by 39%. Calculated clotting time using protein concentrations found in the blood of healthy people was 40.5 s. The most pronounced prolongation of APTT is caused by a decrease in factor X concentration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248291     DOI: 10.1016/s0049-3848(00)00405-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

1.  Blood coagulation dynamics under the conditions of Hageman factor deficiency: a mathematical model.

Authors:  I F Obraztsov; V M Kuz'min; M A Khanin
Journal:  Dokl Biochem Biophys       Date:  2002 Sep-Oct       Impact factor: 0.788

2.  Effect of factor VIII deficiency on generation of thrombin: a biomechanical approach.

Authors:  I F Obraztsov; V M Kuz'min; M A Khanin; A E Kogan; N M Anan'eva; E L Saenko
Journal:  Dokl Biochem Biophys       Date:  2002 Mar-Apr       Impact factor: 0.788

3.  Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa.

Authors:  Wenman Wu; Dipali Sinha; Sergei Shikov; Calvin K Yip; Thomas Walz; Paul C Billings; James D Lear; Peter N Walsh
Journal:  J Biol Chem       Date:  2008-04-25       Impact factor: 5.157

4.  Confinement regulates complex biochemical networks: initiation of blood clotting by "diffusion acting".

Authors:  Feng Shen; Rebecca R Pompano; Christian J Kastrup; Rustem F Ismagilov
Journal:  Biophys J       Date:  2009-10-21       Impact factor: 4.033

5.  Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.

Authors:  Abhishek Gulati; James M Faed; Geoffrey K Isbister; Stephen B Duffull
Journal:  Pharm Res       Date:  2011-08-06       Impact factor: 4.200

6.  Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

Authors:  Rolf Burghaus; Katrin Coboeken; Thomas Gaub; Lars Kuepfer; Anke Sensse; Hans-Ulrich Siegmund; Wolfgang Weiss; Wolfgang Mueck; Joerg Lippert
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

7.  Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers.

Authors:  S Nayak; D Lee; S Patel-Hett; D D Pittman; S W Martin; A C Heatherington; P Vicini; F Hua
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-19

8.  Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.

Authors:  Rolf Burghaus; Katrin Coboeken; Thomas Gaub; Christoph Niederalt; Anke Sensse; Hans-Ulrich Siegmund; Wolfgang Weiss; Wolfgang Mueck; Takahiko Tanigawa; Jörg Lippert
Journal:  Front Physiol       Date:  2014-11-07       Impact factor: 4.566

9.  A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.

Authors:  X Zhou; Drh Huntjens; Rahj Gilissen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-10-09

10.  Identification of disease states associated with coagulopathy in trauma.

Authors:  Yuanyang Zhang; Tie Bo Wu; Bernie J Daigle; Mitchell Cohen; Linda Petzold
Journal:  BMC Med Inform Decis Mak       Date:  2016-09-22       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.